The 1RF brain ablation system saw significant adoption momentum, with nearly half of all historical ablations occurring within the first fiscal quarter of 2026. The 1RF trigeminal nerve ablation system entered a limited commercial launch, demonstrating a competitive advantage by requiring only a single probe placement compared to traditional multiple-placement systems. Management accelerated the drug delivery program by approximately six months, with devices now expected to be available for investigat ...

Group 1 - The conference call is hosted by NeuroOne Medical Technologies Corporation, featuring CEO Dave Rosa and CFO Ron McClurg [1] - The call will include forward-looking statements regarding future operations and financial results, based on management's beliefs and assumptions [2] - There are known and unknown risks that may cause actual results to differ from the forward-looking statements, particularly concerning fiscal 2025 preliminary product revenue [3]

Group 1: Telomir Pharmaceuticals Inc. (TELO) - Shares surged 43% in after-hours trading, climbing from $1.42 to $2.03 on light volume of 213,569 shares, below the average daily volume of 4.67 million [2] - The spike reflects renewed interest in recent in vitro data showing Telomir-1's ability to target additional histone demethylase families, indicating a unique epigenetic profile [3] Group 2: Processa Pharmaceuticals Inc. (PCSA) - Shares rose 32.6% in after-hours trading to $0.37, following a 30.9% gain during the regular session, with a closing price of $0.2790 on volume exceeding 31.9 million shares [4] - The price movement occurred without any official news or updates from the company, suggesting speculative momentum or technical positioning [5] Group 3: Reviva Pharmaceuticals Holdings Inc. (RVPH) - Shares increased 33.7% in after-hours trading to $0.8950 after a regular session gain of 22.8%, closing at $0.6693 with significant trading volume of 34.2 million shares [6] - The rally happened despite no recent official news, with the last update being four days prior regarding a healthcare conference [7] Group 4: NeuroOne Medical Technologies Corp. (NMTC) - Shares rose 9.5% in after-hours trading to $1.09, extending a 7.1% gain during the regular session, with a closing price of $0.9956 and trading volume of 1.21 million shares [8] - The increase followed the announcement of preliminary unaudited product revenue of $9.1 million for fiscal year 2025, up 163% from the prior year, and an upcoming virtual webinar [9] Group 5: BioRestorative Therapies Inc. (BRTX) - Shares edged 4.6% higher in after-hours trading to $1.60, following a modest 2% gain during the regular session, with a closing price of $1.53 and trading volume of 415,798 shares [10] - The increase followed the announcement of a $1.085 million registered direct offering priced at $1.60 per share, with proceeds aimed at advancing clinical trials and other corporate purposes [11]

Core Insights - Biotech stocks experienced strong after-hours gains, driven by Pfizer's announcement of U.S. drug price cuts and a $70 billion investment in domestic manufacturing [1] Group 1: Ovid Therapeutics Inc. (OVID) - Ovid Therapeutics saw a 7.69% increase in after-hours trading, reaching $1.40 after a regular session decline of 7.14% to $1.30 [2] - The stock's regular session selloff was marked by elevated trading volume of over 2.93 million shares, significantly above the average of 2.07 million shares [2] - Recent coverage from Lucid Capital initiated a Buy rating with a price target of $5.50, highlighting Ovid's pipeline assets in Phase 1 trials for drug-resistant epilepsies [3] Group 2: NeuroOne Medical Technologies Corp. (NMTC) - NeuroOne Medical Technologies rose 6.98% in after-hours trading to $0.9506 after a modest decline of 1.27% during the regular session [4] - The trading volume was relatively light at 134,720 shares, below the average of 315,000 shares [4] - The company announced a virtual roadshow webinar scheduled for October 7 to discuss operations and recent FDA clearance [5] Group 3: PepGen Inc. (PEPG) - PepGen experienced a 3.03% rise in after-hours trading, reaching $4.76 after closing at $4.62 [6] - The stock has surged over 120% in the past week due to positive clinical and financial updates [6] - A recent $100 million public offering was completed, expected to support the development of PGN-EDODM1 and PGN-EDO51 [9] Group 4: Reviva Pharmaceuticals Holdings Inc. (RVPH) - Reviva Pharmaceuticals rose 5.81% in after-hours trading to $0.3900 after a 19.56% surge during the regular session [10] - The trading volume was significantly elevated at over 26 million shares, well above the average of 3.9 million shares [10] - The company recently announced a $9 million public offering priced at $0.30 per share [11] Group 5: Anika Therapeutics Inc. (ANIK) - Anika Therapeutics saw a 5.53% increase in after-hours trading, reaching $9.92 after closing at $9.40 [11] - The stock's regular session strength followed a quiet news cycle, with no new filings or press releases [12] - Anika is in focus ahead of its scheduled earnings report on October 30, 2025 [12]

Core Insights - NeuroOne Medical Technologies Corporation announced that Clara, an early patient treated with the OneRF® Ablation System, has surpassed one year seizure-free, significantly improving her quality of life [1][2]. Company Overview - NeuroOne is focused on developing and commercializing minimally invasive and high-definition solutions for various neurological disorders, including epilepsy, Parkinson's disease, and chronic pain [5]. - The OneRF® Ablation System is the first FDA 510(k)-cleared device that utilizes the same sEEG electrode for both diagnostic and therapeutic applications, allowing for monitoring, mapping, and ablation at the bedside [3]. Product Performance - The OneRF® Ablation System has demonstrated seizure reduction or freedom for most patients who have undergone the procedure [3]. - Clara's experience highlights the effectiveness of the OneRF® platform, as she transitioned from experiencing multiple seizures daily to being completely seizure-free [4]. Future Developments - The company plans to leverage the OneRF® technology for additional applications, including the OneRF® Trigeminal Nerve Ablation System aimed at treating facial pain, with a 510(k) submission filed to the FDA in April 2025 [4].

Core Viewpoint - NeuroOne Medical Technologies Corporation has achieved significant milestones and is now fully funded through at least fiscal 2026, with no material impact anticipated from global tariffs [1][3][5]. Company Developments - The company expanded its partnership with Zimmer Biomet, gaining exclusive distribution rights for the OneRF® Ablation System, which includes a $3.0 million upfront license payment [2]. - A successful capital raise of $8.3 million in net proceeds was completed, indicating strong institutional interest in the company's technology platform [4]. - The company is focused on disciplined execution and aims to reach cash flow breakeven while supporting long-term growth plans without additional dilutive financing [5]. Product and Market Opportunities - The anticipated 510(k) submission to the FDA for trigeminal nerve ablation has been accelerated to May 2025, targeting a market of 100,000-200,000 patients suffering from facial pain in the U.S. [6]. - Other growth areas include the Spinal Cord Stimulation (SCS) program and sEEG-Based Drug Delivery Program, with advanced discussions ongoing with strategic partners [7]. Financial Guidance - For fiscal year 2025, product revenues are expected to increase to between $8.0 million and $10.0 million, representing a growth of 132%-190% compared to $3.5 million in fiscal year 2024, with expanded product gross margins of 47%-51% [9].

Core Insights - NeuroOne Medical Technologies Corporation has developed the OneRF® Ablation System, which has successfully treated a pediatric epilepsy patient, Clara Fuller, who previously experienced up to 10 seizures per night, resulting in her being completely seizure-free post-treatment [1][2][3] Company Overview - NeuroOne is focused on improving surgical care options for patients with neurological disorders, including epilepsy, Parkinson's disease, and chronic pain, through minimally invasive and high-definition solutions [4] - The company is exploring additional applications for its technology in areas such as depression, mood disorders, and pain management [4] Technology Impact - The OneRF® technology allows for minimally invasive radiofrequency ablation of seizure-causing brain tissue, significantly improving the quality of life for patients like Clara [2][3] - The successful treatment of Clara Fuller highlights the potential of the OneRF® platform to advance care for patients with debilitating neurological conditions [3]